Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study Comparing Efficacy and Safety of LY01011 and Xgeva®(Denosumab) in Patients With Bone Metastases From Solid Tumors

Next Previous
Trial Profile

A Phase III Study Comparing Efficacy and Safety of LY01011 and Xgeva®(Denosumab) in Patients With Bone Metastases From Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Calcium; Vitamin D
  • Indications Bone metastases; Multiple myeloma; Osteoporosis
  • Focus Therapeutic Use
  • Sponsors Luye Pharma Group

Most Recent Events

  • 06 Jun 2023 Primary endpoint has been met (Natural logarithm change from baseline to week 13 in uNTx/uCr), according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 06 Jun 2023 Status changed to active, no longer recruiting, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top